PLRX

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Pliant Therapeutics, Inc. (PLRX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.5
EV / EBITDA 0.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -36.6%
Price Return 12M -61.3%
Catalyst Signal 0.00
Market Cap $43.2M
TTM Revenue N/A
Price / Sales N/A
ROE -50.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B+ (3.7) C- (2.0) C- (1.9) C- (1.9) C+ (2.6) C (2.4)
2026-11-07 B+ (3.8) C- (2.0) C- (1.9) C (2.2) C+ (2.7) C+ (2.5)
2026-10-31 B+ (3.6) C- (1.9) C- (2.0) C (2.2) C+ (2.7) C (2.5)
2026-10-24 B+ (3.6) C- (1.9) C- (2.0) C- (2.1) C+ (2.6) C (2.5)
2026-10-17 B+ (3.7) C- (1.9) C- (2.0) C (2.2) C+ (2.6) C (2.5)
Page 1 of 7